Loading stock analysis…
Evidence Synthesis
Last synthesized: 23 Aug 2026, 02:44
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
Tornotpharma's 75.98% gross margin accelerated to, up from 21.76%.
The company's .8% revenue growth yoy accelerated, up from -8.2%. Despite this, daily volume decreased by .465 or -0.07% from the previous day.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 75.98 % | 21.76 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 21.76 % | 13.87 | ▲ |
| REVENUE_GROWTH_YOY | 54.8 % | -8.2 | ▲ |
| EPS_ACTUAL | 17.748 INR | 19.001 | ▼ |
| EPS_SURPRISE_PERCENT | 0.016 % | 0.018 | ▼ |
| PRICE_CHANGE_PERCENT | -2.168 % | — | - |
| DAILY_VOLUME | 2,26,263 shares | 6,58,618 | ▼ |
| CLOSE_PRICE | 4,896.5 INR | 5,005 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.76 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 7 count | 16 | ▼ |
| TARGET_PRICE_PREMIUM | 10.01 % | — | - |